Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiaolu Su

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Lancet (London, England)|January 31, 2016
1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysisGregg W Stone, Runlin Gao, Takeshi Kimura, et al.
The American Journal of Cardiology|January 25, 2011
Three-year results of safety and efficacy of the everolimus-eluting coronary stent in women (from the SPIRIT III randomized clinical trial)Vivian G Ng, Alexandra J Lansky, James B Hermiller, et al.
American Heart Journal|September 21, 2015
Evaluation of a fully bioresorbable vascular scaffold in patients with coronary artery disease: design of and rationale for the ABSORB III randomized trialDean J Kereiakes, Stephen G Ellis, Jeffrey J Popma, et al.
Journal of the American College of Cardiology|December 15, 2010
Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System)Dean J Kereiakes, Donald E Cutlip, Robert J Applegate, et al.
JAMA|April 24, 2008
Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trialGregg W Stone, Mark Midei, William Newman, et al.
Journal of the American College of Cardiology|August 16, 2005
The Frontier stent registry: safety and feasibility of a novel dedicated stent for the treatment of bifurcation coronary artery lesionsThierry Lefèvre, John Ormiston, Giulio Guagliumi, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|June 17, 2009
Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trialAlexandra J Lansky, Vivian G Ng, Halil Mutlu, et al.
Circulation. Cardiovascular Interventions|March 23, 2012
Periprocedural myocardial infarction in a randomized trial of everolimus-eluting and Paclitaxel-eluting coronary stents: frequency and impact on mortality according to historic versus universal definitionsM Hassan Pervaiz, Poornima Sood, Krishnankutty Sudhir, et al.
JACC. Cardiovascular Interventions|January 15, 2011
Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trialsAdriano Caixeta, Alexandra J Lansky, Patrick W Serruys, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|April 12, 2020
Left ventricular assist systems and infection-related outcomes: A comprehensive analysis of the MOMENTUM 3 trialChetan B Patel, Laura Blue, Barbara Cagliostro, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Lancet (London, England)|January 31, 2016
1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysisGregg W Stone, Runlin Gao, Takeshi Kimura, et al.
The American Journal of Cardiology|January 25, 2011
Three-year results of safety and efficacy of the everolimus-eluting coronary stent in women (from the SPIRIT III randomized clinical trial)Vivian G Ng, Alexandra J Lansky, James B Hermiller, et al.
American Heart Journal|September 21, 2015
Evaluation of a fully bioresorbable vascular scaffold in patients with coronary artery disease: design of and rationale for the ABSORB III randomized trialDean J Kereiakes, Stephen G Ellis, Jeffrey J Popma, et al.
Journal of the American College of Cardiology|December 15, 2010
Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System)Dean J Kereiakes, Donald E Cutlip, Robert J Applegate, et al.
JAMA|April 24, 2008
Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trialGregg W Stone, Mark Midei, William Newman, et al.
Journal of the American College of Cardiology|August 16, 2005
The Frontier stent registry: safety and feasibility of a novel dedicated stent for the treatment of bifurcation coronary artery lesionsThierry Lefèvre, John Ormiston, Giulio Guagliumi, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|June 17, 2009
Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trialAlexandra J Lansky, Vivian G Ng, Halil Mutlu, et al.
Circulation. Cardiovascular Interventions|March 23, 2012
Periprocedural myocardial infarction in a randomized trial of everolimus-eluting and Paclitaxel-eluting coronary stents: frequency and impact on mortality according to historic versus universal definitionsM Hassan Pervaiz, Poornima Sood, Krishnankutty Sudhir, et al.
JACC. Cardiovascular Interventions|January 15, 2011
Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trialsAdriano Caixeta, Alexandra J Lansky, Patrick W Serruys, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|April 12, 2020
Left ventricular assist systems and infection-related outcomes: A comprehensive analysis of the MOMENTUM 3 trialChetan B Patel, Laura Blue, Barbara Cagliostro, et al.
Pageof 5